SG11201407613RA - Process for making hydroxylated cyclopentylpyrimidine compounds - Google Patents
Process for making hydroxylated cyclopentylpyrimidine compoundsInfo
- Publication number
- SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA SG 11201407613R A SG11201407613R A SG 11201407613RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- boulder
- colorado
- array biopharma
- walnut street
- Prior art date
Links
- KHXLVDUXFUNEQQ-UHFFFAOYSA-N 2-cyclopentylpyrimidine Chemical class C1CCCC1C1=NC=CC=N1 KHXLVDUXFUNEQQ-UHFFFAOYSA-N 0.000 title abstract 3
- 241000758789 Juglans Species 0.000 abstract 2
- 235000009496 Juglans regia Nutrition 0.000 abstract 2
- 235000020234 walnut Nutrition 0.000 abstract 2
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]-1-piperazinyl]-3-(propan-2-ylamino)-1-propanone Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 abstract 1
- LTFBFZBWUKWXID-UHFFFAOYSA-N 1h-cyclopenta[d]pyrimidine Chemical class N1=CNC2=CC=CC2=C1 LTFBFZBWUKWXID-UHFFFAOYSA-N 0.000 abstract 1
- 101000582929 Homo sapiens Plasmolipin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100030265 Plasmolipin Human genes 0.000 abstract 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/30—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648421P | 2012-05-17 | 2012-05-17 | |
| US201361785281P | 2013-03-14 | 2013-03-14 | |
| PCT/US2013/041624 WO2013173736A1 (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407613RA true SG11201407613RA (en) | 2015-01-29 |
Family
ID=48534507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407613RA SG11201407613RA (en) | 2012-05-17 | 2013-05-17 | Process for making hydroxylated cyclopentylpyrimidine compounds |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9309204B2 (https=) |
| EP (1) | EP2861583B1 (https=) |
| JP (1) | JP6214636B2 (https=) |
| KR (1) | KR20150020211A (https=) |
| CN (1) | CN104487430B (https=) |
| AU (1) | AU2013262568B2 (https=) |
| BR (1) | BR112014028570A2 (https=) |
| CA (1) | CA2873653A1 (https=) |
| DK (1) | DK2861583T3 (https=) |
| ES (1) | ES2588878T3 (https=) |
| IL (1) | IL235714A0 (https=) |
| MA (1) | MA37649B1 (https=) |
| MX (1) | MX2014013865A (https=) |
| PL (1) | PL2861583T3 (https=) |
| RU (1) | RU2014151017A (https=) |
| SG (1) | SG11201407613RA (https=) |
| SI (1) | SI2861583T1 (https=) |
| WO (1) | WO2013173736A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX350443B (es) | 2012-05-17 | 2017-09-06 | Genentech Inc | Proceso para hacer compuestos de aminoácidos. |
| CN104471070B (zh) | 2012-05-17 | 2018-09-25 | 基因泰克公司 | 制备羟基化环戊并嘧啶化合物和其盐的方法 |
| HRP20200992T1 (hr) | 2012-05-17 | 2020-10-16 | Genentech, Inc. | Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci |
| AU2013262505B2 (en) | 2012-05-17 | 2017-09-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| ES2765511T3 (es) | 2013-11-15 | 2020-06-09 | Hoffmann La Roche | Procesos para la preparación de compuestos de pirimidinilciclopentano |
| SG11201601813UA (en) * | 2013-11-27 | 2016-04-28 | Sunshine Lake Pharma Co Ltd | Processes for preparing dihydropyrimidine derivatives and intermediates thereof |
| ES2749100T3 (es) * | 2014-09-26 | 2020-03-19 | Hoffmann La Roche | Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina |
| IL295929A (en) | 2020-06-16 | 2022-10-01 | Hoffmann La Roche | Process for making hydroxylated cyclopentylpyrimidine compounds |
| KR102689151B1 (ko) * | 2021-09-06 | 2024-07-29 | 연세대학교 산학협력단 | Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09506369A (ja) | 1993-12-12 | 1997-06-24 | アグロジーン・リミテッド | 菌類感染から植物を保護するための新規方法 |
| AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
| US6201023B1 (en) | 1997-06-10 | 2001-03-13 | Agrogene Ltd. | Methods and compositions to protect crops against plant parasitic nematodes |
| EP0982300A3 (en) | 1998-07-29 | 2000-03-08 | Societe Civile Bioprojet | Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications |
| CA2363169A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| CN1178931C (zh) * | 1999-06-03 | 2004-12-08 | 帝国脏器制药株式会社 | 取代吡唑化合物 |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| JP4550811B2 (ja) | 2003-06-09 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | パピローマウイルスのインヒビター |
| CA2546754A1 (en) | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| US8927546B2 (en) | 2006-02-28 | 2015-01-06 | Dart Neuroscience (Cayman) Ltd. | Therapeutic piperazines |
| UA95641C2 (xx) | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| JP5157576B2 (ja) | 2007-05-14 | 2013-03-06 | 住友化学株式会社 | 光学活性２−アルキル−１，１，３−トリアルコキシカルボニルプロパンの製造方法 |
| CN101918373B (zh) * | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| EP2209775A1 (en) | 2007-10-09 | 2010-07-28 | UCB Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| NZ586346A (en) * | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| AU2009303475B2 (en) * | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| CN102459165B (zh) | 2009-04-15 | 2015-09-02 | Abbvie公司 | 抗病毒化合物 |
| MX2012004780A (es) | 2009-10-23 | 2012-08-23 | Lilly Co Eli | Inhibidores de akt. |
| EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
| WO2012177925A1 (en) | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene |
| CN104471070B (zh) | 2012-05-17 | 2018-09-25 | 基因泰克公司 | 制备羟基化环戊并嘧啶化合物和其盐的方法 |
| AU2013262505B2 (en) | 2012-05-17 | 2017-09-21 | Array Biopharma Inc. | Process for making hydroxylated cyclopentylpyrimidine compounds |
| MX350443B (es) | 2012-05-17 | 2017-09-06 | Genentech Inc | Proceso para hacer compuestos de aminoácidos. |
| WO2014071194A2 (en) | 2012-11-01 | 2014-05-08 | Katz Robert S | Methods for treating fibromyalgia |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2014150395A1 (en) | 2013-03-15 | 2014-09-25 | Shifa Biomedical Corporation | Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases |
-
2013
- 2013-05-17 RU RU2014151017A patent/RU2014151017A/ru not_active Application Discontinuation
- 2013-05-17 ES ES13725533.7T patent/ES2588878T3/es active Active
- 2013-05-17 KR KR20147035262A patent/KR20150020211A/ko not_active Withdrawn
- 2013-05-17 SI SI201330302A patent/SI2861583T1/sl unknown
- 2013-05-17 CN CN201380037994.8A patent/CN104487430B/zh active Active
- 2013-05-17 CA CA2873653A patent/CA2873653A1/en not_active Abandoned
- 2013-05-17 MA MA37649A patent/MA37649B1/fr unknown
- 2013-05-17 PL PL13725533.7T patent/PL2861583T3/pl unknown
- 2013-05-17 WO PCT/US2013/041624 patent/WO2013173736A1/en not_active Ceased
- 2013-05-17 US US14/401,091 patent/US9309204B2/en active Active
- 2013-05-17 MX MX2014013865A patent/MX2014013865A/es unknown
- 2013-05-17 DK DK13725533.7T patent/DK2861583T3/en active
- 2013-05-17 SG SG11201407613RA patent/SG11201407613RA/en unknown
- 2013-05-17 BR BR112014028570A patent/BR112014028570A2/pt not_active IP Right Cessation
- 2013-05-17 AU AU2013262568A patent/AU2013262568B2/en not_active Ceased
- 2013-05-17 JP JP2015512890A patent/JP6214636B2/ja active Active
- 2013-05-17 EP EP13725533.7A patent/EP2861583B1/en active Active
-
2014
- 2014-11-13 IL IL235714A patent/IL235714A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2873653A1 (en) | 2013-11-21 |
| JP6214636B2 (ja) | 2017-10-18 |
| MX2014013865A (es) | 2015-05-07 |
| EP2861583A1 (en) | 2015-04-22 |
| CN104487430A (zh) | 2015-04-01 |
| US20150099881A1 (en) | 2015-04-09 |
| AU2013262568A1 (en) | 2015-01-22 |
| RU2014151017A (ru) | 2016-07-10 |
| IL235714A0 (en) | 2015-02-01 |
| PL2861583T3 (pl) | 2016-12-30 |
| KR20150020211A (ko) | 2015-02-25 |
| AU2013262568B2 (en) | 2017-08-31 |
| HK1208673A1 (en) | 2016-03-11 |
| MA37649B1 (fr) | 2017-03-31 |
| EP2861583B1 (en) | 2016-06-29 |
| MA37649A1 (fr) | 2016-06-30 |
| WO2013173736A1 (en) | 2013-11-21 |
| US9309204B2 (en) | 2016-04-12 |
| DK2861583T3 (en) | 2016-10-03 |
| CN104487430B (zh) | 2016-08-24 |
| SI2861583T1 (sl) | 2016-10-28 |
| JP2015518837A (ja) | 2015-07-06 |
| ES2588878T3 (es) | 2016-11-07 |
| BR112014028570A2 (pt) | 2018-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407613RA (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201407591PA (en) | Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof | |
| SG11201807834WA (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201408186TA (en) | Pyridinone and pyridazinone derivatives | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201408271VA (en) | Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases | |
| SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
| SG11201407458XA (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
| SG11201403402VA (en) | Compounds |